- Precision Medicine: Genetic testing is the foundation of precision medicine, allowing for treatments tailored to individual DNA profiles.
- Pharmacogenomics: This field uses genetic data to improve drug safety and efficacy, exemplified by targeted therapies like Herceptin.
- Oncology Advancements: Genetic markers are critical for early cancer detection and the development of personalized oncology treatment plans.
- Ethical Protections: Regulations like the Genetic Information Nondiscrimination Act (GINA) are vital for maintaining patient privacy and trust.
What genetic testing reveals about DNA and health risk
genetic testing is a process that analyzes DNA to identify specific changes, or variants, that may affect health. These changes can indicate an individual's predisposition to certain diseases, confirm a diagnosis, reveal carrier status for inherited conditions, or inform how a person is likely to respond to specific medications.
The applications are broad. In cancer risk assessment, for example, testing for BRCA1 and BRCA2 gene mutations helps guide both preventive strategies and treatment decisions for breast and ovarian cancer. In clinical research, the same principle applies: identifying the right genetic variant in the right patient is often the first step toward determining eligibility for a precision therapy.
How precision medicine uses genetic profiles to improve treatment
Precision medicine uses genetic information to match patients with the treatments most likely to work for them. Rather than applying a single standard of care across a population, it accounts for the genetic variation that influences how individuals experience disease and respond to therapy.
This approach has practical implications across a growing number of therapeutic areas. In psychiatry, for example, genetic tests can guide antidepressant selection by identifying how a patient metabolizes specific drugs. The result is a more informed treatment decision, reducing the trial-and-error cycle that patients and clinicians often face.
How pharmacogenomics shapes drug development and treatment response
Pharmacogenomics examines how genetic differences influence a patient's response to medications. It operates on two levels.
In drug development, pharmacogenomic insights help identify which patient subgroups are most likely to benefit from a therapy. The development of Herceptin for HER2-positive breast cancer patients is a well-known example: the drug was designed to target a specific genetic marker, meaning that identifying HER2 status through testing is a prerequisite for treatment.
In clinical practice, pharmacogenomics informs how existing medications are prescribed. A patient's DNA can affect how their body processes certain drugs, which means that genetic insights can be critical in choosing the right medication and dosage. This is particularly relevant in therapeutic areas like oncology, cardiology, and psychiatry, where response variability is high.
For clinical research sponsors, pharmacogenomics is increasingly central to trial design. Identifying the right genetic profile before enrollment reduces the risk of poor response rates and improves the likelihood of demonstrating efficacy in genetically defined cohorts.
The role of genetic testing in cancer detection and treatment
Oncology is one of the most established applications of genetic testing in both clinical care and drug development. Testing enables clinicians to identify specific genetic markers associated with different cancer types, which informs decisions at multiple stages: early detection, diagnosis, and treatment selection.
In management of colorectal cancer, for example, genomic testing helps determine whether a tumor carries specific mutations that affect how it responds to therapy. This allows clinicians to match patients with targeted treatments rather than relying solely on broader chemotherapy regimens.
For clinical trial sponsors, oncology programs increasingly require genetic confirmation as an enrollment criterion. This means that the ability to test, identify, and qualify patients based on tumor genomics is directly tied to recruitment feasibility and trial timelines.
Ethical and privacy considerations in genetic testing
As genetic testing becomes more widely used in research and clinical care, it raises important questions around privacy, consent, and data use. Patients need to understand what their genetic information reveals, how it will be stored, and who will have access to it.
Regulatory frameworks such as the Genetic Information Nondiscrimination Act (GINA) provide protections against genetic discrimination in employment and health insurance. These protections are important, but they are not sufficient on their own.
Genetic counseling plays a critical role in helping patients interpret results, understand implications for themselves and their families, and make informed decisions about participation in research. In clinical trial settings, counseling support helps ensure that consent is meaningful rather than procedural.
A webinar featuring Sano’s Head of Quality and Regulatory explores these regulatory and ethical considerations in depth.
Emerging applications of genetic testing across disease areas
The scope of genetic testing continues to expand across therapeutic areas and research models.
In rare disease, genetic testing is increasingly central to diagnosis and trial eligibility, particularly as gene therapies advance toward clinical use. In neurodegenerative conditions like Alzheimer’s, research into genetic risk factors is informing both preventive strategies and the design of early-intervention trials.
Beyond individual studies, the ability to build and maintain genetically characterized patient populations creates long-term value. Recontactable cohorts, where participants have consented to future engagement, allow sponsors to move faster when new programs launch. This shift, from single-use recruitment to longitudinal genetic engagement, is redefining how patient data supports precision medicine over time.
Genetic testing is the mechanism through which precision therapies are matched to the right patients, and the foundation on which modern trial designs are built. For sponsors running genetically stratified or rare disease programs, the ability to integrate testing, counseling, and patient engagement into a single workflow is a structural advantage.
To learn more about how Sano supports genetic testing across the clinical research lifecycle, get in touch.